MedPath

HEPTARES THERAPEUTICS LIMITED

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:10

Trial Phases

2 Phases

Phase 1:10
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (90.9%)
Phase 2
1 (9.1%)

Measurement of HTL0016878 in Cerebrospinal Fluid

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2021-04-19
Last Posted Date
2021-04-19
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
16
Registration Number
NCT04849286
Locations
🇬🇧

MAC Clinical Research, Manchester, United Kingdom

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-07-08
Last Posted Date
2021-07-07
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
8
Registration Number
NCT04462263
Locations
🇬🇧

Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo oral capsule
First Posted Date
2018-12-24
Last Posted Date
2021-04-29
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
71
Registration Number
NCT03785054
Locations
🇬🇧

Covance, Leeds, West Yorkshire, United Kingdom

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Phase 2
Withdrawn
Conditions
Dementia With Lewy Bodies
Interventions
Drug: Placebo
First Posted Date
2018-07-19
Last Posted Date
2019-10-01
Lead Sponsor
Heptares Therapeutics Limited
Registration Number
NCT03592862
Locations
🇯🇵

Nishitaga Hospital, Sendai, Japan

🇯🇵

Kagawa Prefectural Central Hospital, Takamatsu, Japan

🇯🇵

Kurumi Clinic, Tokyo, Japan

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2018-03-07
Last Posted Date
2018-07-20
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
60
Registration Number
NCT03456349
Locations
🇪🇸

Syneos, Barcelona, Spain

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.